AVI BioPharma Announces Conference Call and Webcast on Monday, April 2, 2012, to Discuss Top-Line Data Results From the Phase...
31 März 2012 - 2:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced it will hold a conference call at
8:00 a.m. EDT (5:00 a.m. PDT) on Monday, April 2, 2012 to discuss
top-line results from its Phase IIb study evaluating eteplirsen for
the treatment of Duchenne Muscular Dystrophy (DMD).
The conference call may be accessed by dialing 800.561.2718 for
domestic callers and 617.614.3525 for international callers. The
passcode for the call is 99858553. Please specify to the operator
that you would like to join the "AVI BioPharma Phase IIb Top-Line
Data Results Call." The conference call will be webcast live under
the events section of AVI's website at www.avibio.com and will be
archived there following the call for 90 days. Please connect to
AVI's website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About AVI BioPharma AVI BioPharma is
focused on the discovery and development of novel RNA-based
therapeutics for rare and infectious diseases, as well as other
select disease targets. Applying pioneering technologies developed
and optimized by AVI, the Company is able to target a broad range
of diseases and disorders through distinct RNA-based mechanisms of
action. Unlike other RNA-based approaches, AVI's technologies can
be used to directly target both messenger RNA (mRNA) and precursor
messenger RNA (pre-mRNA) to either down-regulate (inhibit) or
up-regulate (promote) the expression of targeted genes or proteins.
By leveraging a highly differentiated RNA-based technology
platform, AVI has built a pipeline of potentially transformative
therapeutic agents, including eteplirsen, which is in clinical
development for the treatment of Duchenne muscular dystrophy, and
multiple drug candidates that are in clinical development for the
treatment of infectious diseases. For more information, visit
www.avibio.com.
AVI Investor and Media Contact: Erin Cox 425.354.5140 Email
Contact AVI Media Contact: David Schull 858.717.2310 or
212.845.4271 Email Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Sarepta Therapeutics, Inc. (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere AVI BioPharma, Inc. News-Artikel